PRODUCTION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST AND INTERLEUKIN-1 DURING HEMODIALYSIS WITH CELLULOSE MEMBRANES

被引:5
|
作者
FRITH, SE [1 ]
HOENICH, NA [1 ]
REDFERN, CPF [1 ]
GOODSHIP, THJ [1 ]
机构
[1] UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MED, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND
来源
关键词
CHRONIC RENAL FAILURE; HEMODIALYSIS; HEMODIALYSIS MEMBRANE; BIOCOMPATIBILITY; INTERLEUKIN; 1; INTERLEUKIN 1 RECEPTOR ANTAGONIST;
D O I
10.1177/039139889401700906
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
An in vivo cross-over study has investigated plasma and cellular levels of IL-1 (IL-1 alpha IL-1 beta and IL-1Ra) when using Cuprophan (C) and cellulose triacetate (CTA) membranes to assess the roles of complement activation and dialysate endotoxin content in the induction of cytokines during the dialysis procedure. The mean C5a level during Cuprophan dialysis was 29.9 +/- 0.63 ng/ml (Mean +/- SEM), while for the cellulose triacetate dialysis was 3.09 +/- 0.7 ng/ml. The endotoxin content of the dialysate was 0.31 +/- 0.34 EU/ ml and 0.68 +/- 1.39 EU/ml. These two factors failed to produce measurable changes in plasma or cellular IL-1 alpha and IL-1 beta levels during treatment. The plasma IL-1Ra levels predialysis were similar to those for normal controls (CTA 769 +/- 156 ng/ml, C739 +/- 93, normal controls 635 +/- 33) with a considerable day to day variation. A membrane independent fall in plasma IL-1Ra at 15 minutes was noted (CTA 420 +/- 92 ng/ml, C 503 +/- 139) with a return to pre-dialysis levels by the end of treament. Cellular IL-1Ra levels pre-dialysis were similar to the normal group - (CTA 1904 +/- 291 ng/ml, C 1564 +/- 292 and normal control 1971 +/- 368). However, on average, the values when using cellulose triacetate were 655 +/- 623 pg/ml higher than for Cuprophan (p=0.03). These findings indicate that the measurement of plasma cytokine levels is of limited use in the study of cytokine induction by the haemodialysis procedure and that IL-1Ra may be a better indicator of the host response fo cytokine stimuli during treatment. However, a considerable infer-patient and intra-treatment variation is present and further studies are required to elucidate the factors involved.
引用
收藏
页码:478 / 487
页数:10
相关论文
共 50 条
  • [31] ROLE OF INTERLEUKIN-1 AND THE THERAPEUTIC POTENTIAL OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN SEPSIS
    FISHER, CJ
    OPAL, SM
    LOWRY, SF
    SADOFF, JC
    LABRECQUE, JF
    DONOVAN, HC
    LOOKABAUGH, JL
    LEMKE, J
    PRIBBLE, JP
    STROMATT, SC
    VIGERS, GP
    RUSSELL, DA
    THOMPSON, RC
    CIRCULATORY SHOCK, 1994, 44 (01) : 1 - 8
  • [32] INHIBITION BY INTERLEUKIN-1 RECEPTOR ANTAGONIST OF INVIVO ACTIVITIES OF INTERLEUKIN-1 IN MICE
    MENGOZZI, M
    BERTINI, R
    SIRONI, M
    GHEZZI, P
    LYMPHOKINE AND CYTOKINE RESEARCH, 1991, 10 (05): : 405 - 407
  • [33] The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1
    Dinarello, CA
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (10): : 732 - 734
  • [34] Pregnancy induced changes in interleukin-1β and interleukin-1 receptor antagonist in rats
    Fewell, JE
    Fofie, AEA
    FASEB JOURNAL, 2002, 16 (05): : A872 - A872
  • [36] Expression of interleukin-1α and interleukin-1 receptor antagonist in gingival keratinocytes.
    Yang, QB
    Izumi, Y
    Sueda, T
    JOURNAL OF DENTAL RESEARCH, 1999, 78 (05) : 1122 - 1122
  • [37] Balance of interleukin-1β and interleukin-1 receptor antagonist in human periapical lesions
    Shimauchi, H
    Takayama, S
    Imai-Tanaka, T
    Okada, H
    JOURNAL OF ENDODONTICS, 1998, 24 (02) : 116 - 119
  • [38] Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease - Discussion
    Mahida, Y
    Cominelli, F
    Jewell, DP
    Elson, CO
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 : 54 - 54
  • [39] Interleukin-1β and interleukin-1 receptor antagonist gene polymorphisms in rheumatoid arthritis
    Huang, CM
    Tsai, FJ
    Wu, JY
    Wu, MC
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2001, 30 (04) : 225 - 228
  • [40] Interleukin-1β and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis
    van der Paardt, M
    Crusius, JBA
    García-González, MA
    Baudoin, P
    Kostense, PJ
    Alizadeh, BZ
    Dijkmans, BAC
    Peña, AS
    van der Horst-Bruinsma, IE
    RHEUMATOLOGY, 2002, 41 (12) : 1419 - 1423